Astellas Moves For Ouster Of CV Board That Rejected Hostile Bid
This article was originally published in PharmAsia News
Executive Summary
The next time shareholders of U.S.-based CV Therapeutics meet, Astellas Pharma plans to move to oust four of CV's directors. No date has been set for that meeting to consider an Astellas offer to buy the firm that the directors rejected. Astellas said it would follow the ouster with a proposal to name two of the replacement directors. Astellas launched a hostile bid for the company in February. (Click here for more - a subscription may be required